Originally published January 18 2005
Early Ritalin use could lead to depression in adulthood
by Mike Adams (see all articles by this author)
Children who take the drug Ritalin may be at greater risk for depression when they become adults. The medication is given to children believed to be hyperactive—but the diagnosis can often be wrong. Misdiagnosis, combined with Ritalin use, can lead to clinical depression in adulthood, according to a study conducted by the National Institutes of Health and McLean Hospital/Harvard Medical School. Three to 12 percent of children suffer from hyperactivity, or attention deficit disorder.
- A new study conducted in rats by the National Institutes of Health (NIH) and McLean Hospital/Harvard Medical School suggests that the misdiagnosis of attention-deficit hyperactivity disorder (ADHD) combined with prescription drug use in children may lead to a higher risk of developing depressive symptoms in adulthood.
- This work, released at the annual American College of Neuropsychopharmacology (ACNP) conference in Puerto Rico, is among the first to examine the effects of early Ritalin exposure in rats on behavior and brain function during the later periods of life.
- "Attention-deficit hyperactivity disorder can be a serious medical problem for children and their parents," says lead researcher William Carlezon, Ph.D., director of McLean Hospital's Behavioral Genetics Laboratory and associate professor of psychiatry at Harvard Medical School.
- Ritalin is a generic medication prescribed for children with attention-deficit hyperactivity disorder (ADHD), a condition that consists of a persistent pattern of abnormally high level of activity, impulsivity, and/or inattention.
- Because most children show some of these behaviors of inattention and hyperactivity at times, the diagnosis of ADHD is a complex process that should involve specialists.
- "Ritalin can be highly effective in the treatment of ADHD, but our work highlights the importance of getting a proper diagnosis", states Carlezon.
- The mission of ACNP is to further research and education in neuropsychopharmacology and related fields in the following ways: promoting the interaction of a broad range of scientific disciplines of brain and behavior in order to advance the understanding of prevention and treatment of disease of the nervous system including psychiatric, neurological, behavioral and addictive disorders; encouraging scientists to enter research careers in fields related to these disorders and their treatment; and ensuring the dissemination of relevant scientific advances.
All content posted on this site is commentary or opinion and is protected under Free Speech. Truth Publishing LLC takes sole responsibility for all content. Truth Publishing sells no hard products and earns no money from the recommendation of products. NaturalNews.com is presented for educational and commentary purposes only and should not be construed as professional advice from any licensed practitioner. Truth Publishing assumes no responsibility for the use or misuse of this material. For the full terms of usage of this material, visit www.NaturalNews.com/terms.shtml